Formation Bio Drug Development Accelerator Fund pairs dedicated capital with the company's AI-native development platform to scale its portfolio of clinical-stage medicines

Formation Bio药物研发加速基金将专用资本与该公司原生的AI开发平台相结合，以扩大其临床阶段药物组合的规模

NEW YORK

纽约

,

，

Oct. 28, 2026

2026年10月28日

/PRNewswire/ --

/美通社/ --

Formation Bio

Formation Bio

, an AI-native pharmaceutical company, today announced the Formation Bio Drug Development Accelerator Fund (the 'Fund'), with $600 million in capital commitments. The Fund is designed to expand the company's portfolio of clinical-stage medicines. Combining dedicated capital with Formation Bio's AI-native development platform and clinical operating infrastructure, the Fund will support the company's ambition to acquire 10–15 drug programs over the next 3–5 years and advance them through key clinical milestones..

Formation Bio 是一家原生人工智能制药公司，今日宣布成立 Formation Bio 药物开发加速基金（“基金”），已获得 6 亿美元的资金承诺。该基金旨在扩大公司临床阶段药物的产品组合。通过将专用资本与 Formation Bio 的原生人工智能开发平台及临床运营基础设施相结合，该基金将支持公司在未来 3 至 5 年内收购 10 至 15 个药物项目，并推动这些项目达成关键临床里程碑。

The Fund's limited partners include leading research foundations, institutional endowments, hospitals, and philanthropic organizations.

该基金的有限合伙人包括领先的研究基金会、机构捐赠基金、医院和慈善组织。

The Fund helps scale Formation's hub-and-spoke model, exclusively financing the acquisition and development of drug programs within Formation Bio's portfolio. Formation Bio serves as the Fund's general partner through a wholly owned subsidiary and has committed its own capital alongside the Fund's limited partners..

该基金助力扩大 Formation 的“中心-辐射”模式，专门用于资助 Formation Bio 产品组合中药物项目的收购与开发。Formation Bio 通过其全资子公司担任该基金的普通合伙人，并与基金的有限合伙人共同投入了自有资金。

Each funded program is housed in a standalone corporate entity supported by Formation Bio's established development organization, keeping the economics of each asset financially distinct, while allowing more capital to be directed toward clinical development rather than toward separate, redundant operating infrastructure within multiple companies.

每个受资助的项目均设立于独立的法人实体中，并由 Formation Bio 成熟的开发组织提供支持，在确保各资产的经济效益保持财务独立的同时，使更多资本能够投向临床开发，而非用于多家公司内部分立且冗余的运营基础设施。

The Fund's limited partners benefit from all of Formation Bio's scientific, clinical and operational expertise and capabilities, both in evaluating programs and executing their development plans..

该基金的有限合伙人受益于 Formation Bio 在科学、临床和运营方面的全部专业知识与能力，涵盖项目评估及执行其开发计划两个方面。

'This Fund gives our LPs access to an important and emerging investment category—individual drug assets—through a capital-efficient structure,' said Benjamine Liu, Co-Founder and CEO of Formation Bio. 'For Formation Bio, it expands the number of promising drugs we can pursue, gives us strategic and financing flexibility, creates paths to liquidity without selling the parent company, and positions us to lower our cost of capital over time.

Formation Bio 联合创始人兼首席执行官 Benjamine Liu 表示：“该基金通过资本高效的结构，让我们的有限合伙人（LPs）能够进入一个重要的新兴投资类别——单体药物资产。对 Formation Bio 而言，它扩大了我们可推进的有前景药物数量，为我们提供了战略和融资灵活性，创造了在不出售母公司的情况下实现流动性的路径，并使我们能够在长期内降低资本成本。”

Together, these advantages address structural challenges in our industry, allow us to develop more drugs for patients, and support our ambition to build this generation's enduring pharma company.'.

这些优势共同应对了我们行业中的结构性挑战，使我们能够为患者开发更多药物，并支持我们打造这一代持久发展的制药企业的雄心。

Formation Bio acquires or in-licenses Phase 1 and Phase 2 programs from pharmaceutical companies and biotechs, prioritizing assets with a clear path to clinical proof of concept. The company focuses on diseases with substantial unmet need but limited active development across the industry, targeting major clinical milestones within 2–4 years of acquisition, depending on the program..

Formation Bio 从制药公司和生物技术公司收购或许可引进处于1期和2期阶段的项目，优先选择具有明确临床概念验证路径的资产。该公司专注于那些存在巨大未满足需求但行业内活跃研发有限的疾病领域，旨在根据具体项目情况，在收购后的2至4年内实现重大临床里程碑。

Capital will be deployed according to each program's development needs, allowing Formation Bio to concentrate resources on the most promising opportunities. As the portfolio grows, Formation Bio expects to continuously improve its technology and development capabilities, creating efficiencies that benefit future programs.

资本将根据每个项目的开发需求进行配置，使 Formation Bio 能够将资源集中于最具前景的机会。随着产品组合的不断扩大，Formation Bio 预计将持续提升其技术与开发能力，创造效率优势，从而惠及未来的项目。

Following meaningful clinical progress, the company expects to partner programs with pharmaceutical companies for commercialization or co-commercialization..

在取得有意义的临床进展后，公司期望与制药企业合作，共同推进项目的商业化或联合商业化。

'As a biotech investor and founder, I've seen firsthand how promising medicines can get stranded in company pipelines,' said David Steinberg, Chief Business Officer at Formation Bio. 'The Formation Bio Fund offers a new way to unlock their potential, leveraging the scale and sophistication of an AI-native drug developer.'.

“作为一名生物科技投资者和创始人，我亲眼目睹了诸多前景广阔的药物如何被困在企业的研发管线中，”Formation Bio首席商务官David Steinberg表示。“Formation Bio基金提供了一种释放这些药物潜力的新途径，借助原生AI药物开发者的规模与专业优势。”

The Fund represents an important step toward the company's broader ambition: developing more medicines, more efficiently and with a greater likelihood of success, so that more innovative therapies can reach patients.

该基金标志着公司向更宏大目标迈出的重要一步：以更高效、更高成功率的方式开发更多药物，从而使更多创新疗法能够惠及患者。

'Few applications of AI have the potential to deliver as profound an impact on society as accelerating the development of new medicines,' said Michael Ehlers, Chief Scientific Officer and Head of R&D at Formation Bio. 'This is a meaningful next step for real-world application of AI that expands our ability to bring innovative therapies to patients.'.

“很少有AI应用能像加速新药研发那样，对社会产生如此深远的影响。”Formation Bio首席科学官兼研发主管Michael Ehlers表示。“这是AI在现实世界应用中具有意义的一步，它扩展了我们为患者提供创新疗法的能力。”

About Formation Bio

关于 Formation Bio

Formation Bio is an AI-native pharmaceutical company building a more efficient model for drug development. The company combines deep pharmaceutical and clinical expertise with proprietary technology and AI systems designed to accelerate the development of medicines. Formation Bio acquires and in-licenses clinical-stage drug programs, then applies its technology, operational capabilities and development expertise to advance them toward clinical proof of concept and beyond.

Formation Bio 是一家原生人工智能制药公司，致力于构建更高效的药物研发模式。公司将深厚的药学与临床经验与专有技术及旨在加速药物研发的 AI 系统相结合。Formation Bio 通过收购和授权引进处于临床阶段的药物项目，并运用其技术、运营能力和研发专长，推动这些项目迈向临床概念验证及后续阶段。

The company is headquartered in New York City, with a second office in Boston..

该公司总部位于纽约市，并在波士顿设有第二办公室。

Media Contact

媒体联系人

[email protected]

[email protected]

SOURCE Formation Bio

来源：Formation Bio